Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.
复制标题

核糖体蛋白 L22-like1 (RPL22L1) 在肝细胞癌中通过 ERK 介导索拉非尼敏感性。

DOI:
10.1038/s41420-022-01153-8
复制
发表时间:
2022-08-17
影响因子:
7
通讯作者:
Jin, Yan
Jin, Yan
中科院分区:
医学2区
文献类型:
--
作者:
Zhang, Dongmei;Zhou, Yunzhen;Ma, Yanan;Jiang, Ping;Lv, Hongchao;Liu, Sijia;Mu, Yu;Zhou, Chong;Xiao, Shan;Ji, Guohua;Liu, Peng;Zhang, Ning;Sun, Donglin;Sun, Haiming;Wu, Nan;Jin, Yan

文献摘要

参考文献

被引文献

相似文献

肝细胞癌 (HCC) 的精准医学依赖于经过验证的生物标志物,帮助亚组患者进行靶向治疗。在这里,我们发现了一种新的候选癌基因,即核糖体蛋白 L22-like1 (RPL22L1),它在 HCC 中显着升高,导致 HCC 恶性肿瘤和患者生存不良。功能研究表明 RPL22L1 过度表达加速细胞增殖、迁移、侵袭和索拉非尼耐药。机制研究表明,RPL22L1 激活 ERK 诱导非典型上皮间质转化 (EMT) 进展。重要的是,ERK 抑制剂 (ERKi) 可以增强索拉非尼在 RPL22L1 高 HCC 细胞中的效率。总之,这些数据揭示了 RPL22L1 是指导精准治疗的潜在标志物,可利用 ERKi 增强索拉非尼对 RPL22L1 高 HCC 患者的疗效。
Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here, we identified a novel candidate oncogene, ribosomal protein L22-like1 (RPL22L1), which was markedly elevated in HCC, contributed to HCC malignancy and adverse patient survival. Functional studies indicated RPL22L1 overexpression accelerated cell proliferation, migration, invasion and sorafenib resistance. Mechanism studies revealed that RPL22L1 activated ERK to induce atypical epithelial-to-mesenchymal transition (EMT) progress. Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients.
DOI: 10.1371/journal.pone.0067043
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者:
Huang CJ;Yang SH;Lee CL;Cheng YC;Tai SY;Chien CC
通讯作者: Chien CC
DOI: 10.1158/1535-7163.mct-19-0505
发表时间: 2020-02-01
影响因子: 5.7
作者:
Kidger, Andrew M.;Munck, Joanne M.;Cook, Simon J.
通讯作者: Cook, Simon J.
DOI: 10.1016/j.jhep.2017.03.011
发表时间: 2017-08-01
影响因子: 25.7
作者:
Bertuccio, Paola;Turati, Federica;Negri, Eva
通讯作者: Negri, Eva
DOI: 10.1186/gb-2009-10-1-r2
发表时间: 2009
期刊: Genome biology
影响因子: 12.3
作者:
Balasubramanian S;Zheng D;Liu YJ;Fang G;Frankish A;Carriero N;Robilotto R;Cayting P;Gerstein M
通讯作者: Gerstein M
DOI: 10.3892/ol.2018.9491
发表时间: 2018-11
期刊: Oncology letters
影响因子: 2.9
作者:
Fan S;Liang Z;Gao Z;Pan Z;Han S;Liu X;Zhao C;Yang W;Pan Z;Feng W
通讯作者: Feng W